NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
ID: 354442Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $250K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/354442

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required). This initiative invites applications for interventional clinical trials that are prepared to advance following necessary preparatory work, with the UG3 phase focusing on finalizing trial design and logistics, and the UH3 phase dedicated to full execution and assessment of the trial. The program emphasizes the importance of clinical impact within NIAMS missions, participant engagement from underserved populations, and collaboration with representatives of lived experiences to promote health equity. Interested applicants can submit proposals with budgets capped at $250,000 for the UG3 phase and a project duration of up to five years for the UH3 phase, with a submission deadline of March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-208-Full-Announcement.html
    PAR-24-208.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has announced a funding opportunity for clinical trial implementation via a two-phase cooperative agreement (UG3/UH3). This funding seeks applications for interventional clinical trials that are ready to move forward after necessary preparatory work has been carried out. The UG3 phase supports activities needed to finalize trial design and logistics, while the UH3 phase involves the full execution and assessment of the trial. Key requirements include clear milestone achievement for progression from UG3 to UH3, a focus on clinical impact within NIAMS missions, and the necessity for participant engagement, particularly from underserved populations. Applications with budgets limited to $250,000 for UG3 and up to five years for the UH3 phase can be submitted through Grants.gov, with detailed project timelines and milestones as essential components. The emphasis on collaboration with lived experience representatives underscores a commitment to health equity and inclusive research practices. The anticipated funding awards depend on project viability and scientific merit, promoting innovative approaches in clinical studies targeting arthritis and related disorders.
    Similar Opportunities
    NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3), aimed at supporting interventional clinical trials focused on rheumatic, musculoskeletal, and skin diseases. This initiative encompasses a two-phase approach, where the UG3 phase involves trial preparation and the UH3 phase focuses on trial execution, contingent upon meeting specific milestones. The program emphasizes the importance of developing clinical protocols, obtaining IRB approval, and securing necessary resources, while also promoting health equity by engaging individuals with lived experience in the research process. Interested applicants can apply for funding up to $250,000 for the UG3 phase, with a closing date for submissions set for March 4, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-208.html.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding opportunities through the "Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases" program, specifically under the R61 Clinical Trial mechanism. This initiative aims to support short-term exploratory clinical trials that investigate treatments for rheumatic, musculoskeletal, and skin conditions, with a focus on diverse therapeutic approaches. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and state and local governments, with a maximum budget of $600,000 for a three-year project, not exceeding $300,000 in any single year. Applications must be submitted electronically via Grants.gov, with key deadlines starting from February 4, 2024, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. For more details, visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-24-035.html.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that align with NINDS's mission, focusing on innovative approaches to evaluate drugs, devices, and interventions for neurological disorders. The funding is structured as a cooperative agreement with a maximum support period of five years, where the UG3 phase lasts up to two years, followed by a potential transition to the UH3 phase for executing clinical trials. Interested applicants should note that the application process opens on January 10, 2025, with a submission deadline of March 11, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for investigator-initiated efficacy clinical trials through the NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required) program. This initiative aims to support clinical studies that evaluate drugs, biologics, devices, and various interventions targeting neurological disorders, requiring a phased approach where UG3 planning must precede UH3 execution. The trials must be well-designed with robust scientific rationale and diverse participant inclusion, emphasizing collaboration with patient advocacy groups and national networks. Interested applicants can find more information and application guidelines at the provided NIH link, with a submission deadline of January 9, 2025, and no cost-sharing or matching requirements. For inquiries, contact the NIH OER Webmaster at grantsinfo@nih.gov.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Ancillary Studies to Ongoing Clinical Projects funding opportunity (PAR-23-025), aimed at supporting time-sensitive ancillary studies that enhance scientific knowledge related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). These studies must utilize existing cohorts, data, and biological samples to explore novel research questions that extend beyond the scope of the parent projects, with an emphasis on collaboration between junior and senior researchers. Grants may provide up to $300,000 per year for a duration of up to four years, with applications accepted until December 6, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Exploratory Clinical Trial Grants (R61) to support research in arthritis and musculoskeletal and skin diseases. This funding opportunity aims to facilitate short-term, interventional studies that address critical research questions, particularly those evaluating drug efficacy in rare diseases, without requiring preliminary data. Grants can provide up to $600,000 over three years, with applications due by November 2, 2026. Interested applicants are encouraged to consult with NIH staff during the application process and can find additional information at NIH Grants or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Ancillary Studies to Ongoing Clinical Projects" grant (FON: PAR-24-289), aimed at supporting time-sensitive ancillary studies that leverage existing resources from active clinical projects related to the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This funding opportunity encourages innovative research that enhances the scientific content of parent projects, with eligible studies potentially including interventional trials or observational studies that utilize well-characterized cohorts, data, and biological samples. The total budget for direct costs is capped at $300,000 per year, with projects lasting a maximum of four years, and applications must be submitted electronically by September 5, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.